Sab BiotherapeuticsSABS
13F holders, Q1 2024 (March 31)24holders
1famous investor
$4.54avg. 13F price*
At the end of Q1 2024, 24 institutions reported holding Sab Biotherapeutics Inc. (SABS) in their 13F filings. The largest holders were RTW Investments, LP ($4.2M), BVF Inc. ($4.2M) and Marshall Wace, LLP ($2.1M). One famous investor held it Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Sab Biotherapeutics Inc.
- CUSIP
- 78397T202
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $248K |
| Exits | 1 | $1.6M |
Ownership 24 holders
| RTW Investments, LP | 0.06% | No change | 917,827 | $4.2M |
| BVF Inc. | 0.11% | No change | 917,826 | $4.2M |
| Marshall Wace, LLP | 0.00% | Reduce -90.0% | 459,168 | $2.1M |
| Sessa Capital IM, L.P. | 0.08% | No change | 458,457 | $2.1M |
| Commodore Capital LP | 0.06% | Reduce -90.0% | 183,174 | $832K |
| Vanguard Group Inc. | 0.00% | Add +77.0% | 176,334 | $801K |
| Geode Capital Management, LLC | 0.00% | Add +78.1% | 63,466 | $288K |
| Millennium Management | 0.00% | New | 54,050 | $245K |
| Pathstone Holdings, LLC | 0.00% | No change | 50,650 | $230K |
| First Manhattan Co. Llc. | 0.00% | Reduce -11.5% | 24,577 | $112K |
| Institutional & Family Asset Management, LLC | 0.01% | No change | 19,201 | $87K |
| BlackRock Inc. | 0.00% | Add +20.4% | 6,339 | $29K |
| Osaic Holdings, Inc. | 0.00% | Reduce -2.4% | 4,524 | $21K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -5.7% | 1,436 | $7K |
| Morgan Stanley | 0.00% | Add +4.2% | 1,199 | $5K |
| Spectrum Wealth Counsel, LLC | 0.00% | No change | 503 | $2K |
| Princeton Global Asset Management LLC | 0.00% | New | 500 | $2K |
| GS Investments, Inc. | 0.00% | No change | 200 | $908 |
| JPMorgan Chase & Co. | 0.00% | Add +9.4% | 104 | $472 |
| Wells Fargo & Company | 0.00% | Add +107.5% | 61 | $277 |
| Harbour Investments, Inc. | 0.00% | New | 50 | $227 |
| NewEdge Advisors, LLC | 0.00% | Reduce -3.5% | 14 | $64 |
| Qube Research & Technologies Ltd | 0.00% | Reduce -13.0% | 6 | $27 |
| Royal Bank of Canada | 0.00% | Reduce -11.8% | 6 | $0 |
"% of holder's portfolio" is SABS's weight in each manager's 13F, not the share of Sab Biotherapeutics Inc. the manager owns.